Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy
Abstract Background We evaluated the cross-sectional relationship of duration and dosage of valproate monotherapy on bone mineral density (BMD) in adult patients with epilepsy. Methods The BMD at lumbar level (L2–L4) was measured in consecutive adult epileptic patients receiving long-term (≥ 2 years...
Gespeichert in:
| Veröffentlicht in: | Journal of the neurological sciences 2010-03, Vol.290 (1), p.131-134 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 134 |
|---|---|
| container_issue | 1 |
| container_start_page | 131 |
| container_title | Journal of the neurological sciences |
| container_volume | 290 |
| creator | Triantafyllou, Nikos Lambrinoudaki, Irini Armeni, Elena Evangelopoulos, Eleftheria-Maria Boufidou, Fotini Antoniou, Aris Tsivgoulis, Georgios |
| description | Abstract Background We evaluated the cross-sectional relationship of duration and dosage of valproate monotherapy on bone mineral density (BMD) in adult patients with epilepsy. Methods The BMD at lumbar level (L2–L4) was measured in consecutive adult epileptic patients receiving long-term (≥ 2 years) valproate monotherapy by dual energy X-ray absorptiometry (DXA). Blood samples were collected for total serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D3 and parathormone. Osteopenia and osteoporosis were defined according to the World Health Organization operational BMD definition. Cross-sectional associations were evaluated using Spearman's correlation coefficient. Results A total of 41 patients were studied (mean age 32.3 ± 8.2 years, 12 men, mean duration of valproate monotherapy 10.6 ± 7.4 years). Osteopenia was present in 24% of subjects, while no case of osteoporosis was documented. Duration and dosage of valproate monotherapy did not correlate with BMD. No association was documented between duration or dosage of valproate monotherapy and biochemical parameters. Conclusions Duration of valproate monotherapy does not correlate with decreased BMD in adult patients with epilepsy. No case of osteoporosis was identified in patients treated with valproate for a mean period of more than ten years. These findings indicate that bone metabolism may not be affected by valproate monotherapy. |
| doi_str_mv | 10.1016/j.jns.2009.12.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_883046606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0022510X09010065</els_id><sourcerecordid>733514942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-f2398286590296bec10a7a1833c1437005f3a7d9be8129e21dacf9c37687967a3</originalsourceid><addsrcrecordid>eNqFkk-L1TAUxYMozpvRD-BGshFXrfnTpgmCIMOMCgMuVNBVyEtvndQ0eSbtSL-9Ke-p4EJXgcs5N4ffPQg9oaSmhIoXYz2GXDNCVE1ZTWh7D-2o7GTVSsnvox0hjFUtJZ_P0HnOIyFESKkeorNiaQVr6Q59uRoGsDOOA_YxfK1mSBO-M_6QopkBTzHE-RaSOaw4BryPocxcKAOPewjZzSt2AZt-8XPGP9x8i-HgPBzy-gg9GIzP8Pj0XqBP11cfL99WN-_fvLt8fVPZRqi5GhhXkknRKsKU2IOlxHSGSs4tbXhXgg7cdL3ag6RMAaO9sYOyvBOyU6Iz_AI9P-4tkb8vkGc9uWzBexMgLlkXFKQRgoj_KjvOW9qohhUlPSptijknGPQhucmkVVOiN_R61AW93tBrynRBXzxPT9uX_QT9b8cv1kXw7CQw2Ro_JBOsy390rGQU7Rbz5VEHhdqdg6SzdRAs9C6VU-k-un_GePWX23oXXPnwG6yQx7ikUM6hqc7FoD9sHdkqQhShpR8t_wnVEbVR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733514942</pqid></control><display><type>article</type><title>Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Triantafyllou, Nikos ; Lambrinoudaki, Irini ; Armeni, Elena ; Evangelopoulos, Eleftheria-Maria ; Boufidou, Fotini ; Antoniou, Aris ; Tsivgoulis, Georgios</creator><creatorcontrib>Triantafyllou, Nikos ; Lambrinoudaki, Irini ; Armeni, Elena ; Evangelopoulos, Eleftheria-Maria ; Boufidou, Fotini ; Antoniou, Aris ; Tsivgoulis, Georgios</creatorcontrib><description>Abstract Background We evaluated the cross-sectional relationship of duration and dosage of valproate monotherapy on bone mineral density (BMD) in adult patients with epilepsy. Methods The BMD at lumbar level (L2–L4) was measured in consecutive adult epileptic patients receiving long-term (≥ 2 years) valproate monotherapy by dual energy X-ray absorptiometry (DXA). Blood samples were collected for total serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D3 and parathormone. Osteopenia and osteoporosis were defined according to the World Health Organization operational BMD definition. Cross-sectional associations were evaluated using Spearman's correlation coefficient. Results A total of 41 patients were studied (mean age 32.3 ± 8.2 years, 12 men, mean duration of valproate monotherapy 10.6 ± 7.4 years). Osteopenia was present in 24% of subjects, while no case of osteoporosis was documented. Duration and dosage of valproate monotherapy did not correlate with BMD. No association was documented between duration or dosage of valproate monotherapy and biochemical parameters. Conclusions Duration of valproate monotherapy does not correlate with decreased BMD in adult patients with epilepsy. No case of osteoporosis was identified in patients treated with valproate for a mean period of more than ten years. These findings indicate that bone metabolism may not be affected by valproate monotherapy.</description><identifier>ISSN: 0022-510X</identifier><identifier>EISSN: 1878-5883</identifier><identifier>DOI: 10.1016/j.jns.2009.12.015</identifier><identifier>PMID: 20056251</identifier><identifier>CODEN: JNSCAG</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Absorptiometry, Photon ; Adult ; Age ; Anticonvulsants - administration & dosage ; Anticonvulsants - adverse effects ; Biological and medical sciences ; Biomarkers - analysis ; Biomarkers - blood ; Bone and Bones - drug effects ; Bone and Bones - metabolism ; Bone and Bones - physiopathology ; Bone Density - drug effects ; Bone Density - physiology ; Bone Diseases, Metabolic - chemically induced ; Bone Diseases, Metabolic - pathology ; Bone Diseases, Metabolic - physiopathology ; Bone mineral density ; Bone turnover ; Calcium (blood) ; Chronic Disease ; Cross-Sectional Studies ; Drug Administration Schedule ; Dual energy X-ray absorptiometry ; Epilepsy ; Female ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; Magnesium ; Male ; Medical sciences ; Middle Aged ; Nervous system (semeiology, syndromes) ; Neurology ; Osteopenia ; Osteoporosis ; Osteoporosis - chemically induced ; Osteoporosis - pathology ; Osteoporosis - physiopathology ; Phosphorus ; Time ; Time Factors ; Valproate ; Valproic acid ; Valproic Acid - administration & dosage ; Valproic Acid - adverse effects ; Young Adult</subject><ispartof>Journal of the neurological sciences, 2010-03, Vol.290 (1), p.131-134</ispartof><rights>Elsevier B.V.</rights><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-f2398286590296bec10a7a1833c1437005f3a7d9be8129e21dacf9c37687967a3</citedby><cites>FETCH-LOGICAL-c469t-f2398286590296bec10a7a1833c1437005f3a7d9be8129e21dacf9c37687967a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jns.2009.12.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22606656$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20056251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Triantafyllou, Nikos</creatorcontrib><creatorcontrib>Lambrinoudaki, Irini</creatorcontrib><creatorcontrib>Armeni, Elena</creatorcontrib><creatorcontrib>Evangelopoulos, Eleftheria-Maria</creatorcontrib><creatorcontrib>Boufidou, Fotini</creatorcontrib><creatorcontrib>Antoniou, Aris</creatorcontrib><creatorcontrib>Tsivgoulis, Georgios</creatorcontrib><title>Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy</title><title>Journal of the neurological sciences</title><addtitle>J Neurol Sci</addtitle><description>Abstract Background We evaluated the cross-sectional relationship of duration and dosage of valproate monotherapy on bone mineral density (BMD) in adult patients with epilepsy. Methods The BMD at lumbar level (L2–L4) was measured in consecutive adult epileptic patients receiving long-term (≥ 2 years) valproate monotherapy by dual energy X-ray absorptiometry (DXA). Blood samples were collected for total serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D3 and parathormone. Osteopenia and osteoporosis were defined according to the World Health Organization operational BMD definition. Cross-sectional associations were evaluated using Spearman's correlation coefficient. Results A total of 41 patients were studied (mean age 32.3 ± 8.2 years, 12 men, mean duration of valproate monotherapy 10.6 ± 7.4 years). Osteopenia was present in 24% of subjects, while no case of osteoporosis was documented. Duration and dosage of valproate monotherapy did not correlate with BMD. No association was documented between duration or dosage of valproate monotherapy and biochemical parameters. Conclusions Duration of valproate monotherapy does not correlate with decreased BMD in adult patients with epilepsy. No case of osteoporosis was identified in patients treated with valproate for a mean period of more than ten years. These findings indicate that bone metabolism may not be affected by valproate monotherapy.</description><subject>Absorptiometry, Photon</subject><subject>Adult</subject><subject>Age</subject><subject>Anticonvulsants - administration & dosage</subject><subject>Anticonvulsants - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>Biomarkers - blood</subject><subject>Bone and Bones - drug effects</subject><subject>Bone and Bones - metabolism</subject><subject>Bone and Bones - physiopathology</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - physiology</subject><subject>Bone Diseases, Metabolic - chemically induced</subject><subject>Bone Diseases, Metabolic - pathology</subject><subject>Bone Diseases, Metabolic - physiopathology</subject><subject>Bone mineral density</subject><subject>Bone turnover</subject><subject>Calcium (blood)</subject><subject>Chronic Disease</subject><subject>Cross-Sectional Studies</subject><subject>Drug Administration Schedule</subject><subject>Dual energy X-ray absorptiometry</subject><subject>Epilepsy</subject><subject>Female</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>Magnesium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Osteopenia</subject><subject>Osteoporosis</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - pathology</subject><subject>Osteoporosis - physiopathology</subject><subject>Phosphorus</subject><subject>Time</subject><subject>Time Factors</subject><subject>Valproate</subject><subject>Valproic acid</subject><subject>Valproic Acid - administration & dosage</subject><subject>Valproic Acid - adverse effects</subject><subject>Young Adult</subject><issn>0022-510X</issn><issn>1878-5883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk-L1TAUxYMozpvRD-BGshFXrfnTpgmCIMOMCgMuVNBVyEtvndQ0eSbtSL-9Ke-p4EJXgcs5N4ffPQg9oaSmhIoXYz2GXDNCVE1ZTWh7D-2o7GTVSsnvox0hjFUtJZ_P0HnOIyFESKkeorNiaQVr6Q59uRoGsDOOA_YxfK1mSBO-M_6QopkBTzHE-RaSOaw4BryPocxcKAOPewjZzSt2AZt-8XPGP9x8i-HgPBzy-gg9GIzP8Pj0XqBP11cfL99WN-_fvLt8fVPZRqi5GhhXkknRKsKU2IOlxHSGSs4tbXhXgg7cdL3ag6RMAaO9sYOyvBOyU6Iz_AI9P-4tkb8vkGc9uWzBexMgLlkXFKQRgoj_KjvOW9qohhUlPSptijknGPQhucmkVVOiN_R61AW93tBrynRBXzxPT9uX_QT9b8cv1kXw7CQw2Ro_JBOsy390rGQU7Rbz5VEHhdqdg6SzdRAs9C6VU-k-un_GePWX23oXXPnwG6yQx7ikUM6hqc7FoD9sHdkqQhShpR8t_wnVEbVR</recordid><startdate>20100315</startdate><enddate>20100315</enddate><creator>Triantafyllou, Nikos</creator><creator>Lambrinoudaki, Irini</creator><creator>Armeni, Elena</creator><creator>Evangelopoulos, Eleftheria-Maria</creator><creator>Boufidou, Fotini</creator><creator>Antoniou, Aris</creator><creator>Tsivgoulis, Georgios</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope><scope>7TK</scope></search><sort><creationdate>20100315</creationdate><title>Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy</title><author>Triantafyllou, Nikos ; Lambrinoudaki, Irini ; Armeni, Elena ; Evangelopoulos, Eleftheria-Maria ; Boufidou, Fotini ; Antoniou, Aris ; Tsivgoulis, Georgios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-f2398286590296bec10a7a1833c1437005f3a7d9be8129e21dacf9c37687967a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Absorptiometry, Photon</topic><topic>Adult</topic><topic>Age</topic><topic>Anticonvulsants - administration & dosage</topic><topic>Anticonvulsants - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>Biomarkers - blood</topic><topic>Bone and Bones - drug effects</topic><topic>Bone and Bones - metabolism</topic><topic>Bone and Bones - physiopathology</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - physiology</topic><topic>Bone Diseases, Metabolic - chemically induced</topic><topic>Bone Diseases, Metabolic - pathology</topic><topic>Bone Diseases, Metabolic - physiopathology</topic><topic>Bone mineral density</topic><topic>Bone turnover</topic><topic>Calcium (blood)</topic><topic>Chronic Disease</topic><topic>Cross-Sectional Studies</topic><topic>Drug Administration Schedule</topic><topic>Dual energy X-ray absorptiometry</topic><topic>Epilepsy</topic><topic>Female</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>Magnesium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Osteopenia</topic><topic>Osteoporosis</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - pathology</topic><topic>Osteoporosis - physiopathology</topic><topic>Phosphorus</topic><topic>Time</topic><topic>Time Factors</topic><topic>Valproate</topic><topic>Valproic acid</topic><topic>Valproic Acid - administration & dosage</topic><topic>Valproic Acid - adverse effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Triantafyllou, Nikos</creatorcontrib><creatorcontrib>Lambrinoudaki, Irini</creatorcontrib><creatorcontrib>Armeni, Elena</creatorcontrib><creatorcontrib>Evangelopoulos, Eleftheria-Maria</creatorcontrib><creatorcontrib>Boufidou, Fotini</creatorcontrib><creatorcontrib>Antoniou, Aris</creatorcontrib><creatorcontrib>Tsivgoulis, Georgios</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of the neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Triantafyllou, Nikos</au><au>Lambrinoudaki, Irini</au><au>Armeni, Elena</au><au>Evangelopoulos, Eleftheria-Maria</au><au>Boufidou, Fotini</au><au>Antoniou, Aris</au><au>Tsivgoulis, Georgios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy</atitle><jtitle>Journal of the neurological sciences</jtitle><addtitle>J Neurol Sci</addtitle><date>2010-03-15</date><risdate>2010</risdate><volume>290</volume><issue>1</issue><spage>131</spage><epage>134</epage><pages>131-134</pages><issn>0022-510X</issn><eissn>1878-5883</eissn><coden>JNSCAG</coden><abstract>Abstract Background We evaluated the cross-sectional relationship of duration and dosage of valproate monotherapy on bone mineral density (BMD) in adult patients with epilepsy. Methods The BMD at lumbar level (L2–L4) was measured in consecutive adult epileptic patients receiving long-term (≥ 2 years) valproate monotherapy by dual energy X-ray absorptiometry (DXA). Blood samples were collected for total serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D3 and parathormone. Osteopenia and osteoporosis were defined according to the World Health Organization operational BMD definition. Cross-sectional associations were evaluated using Spearman's correlation coefficient. Results A total of 41 patients were studied (mean age 32.3 ± 8.2 years, 12 men, mean duration of valproate monotherapy 10.6 ± 7.4 years). Osteopenia was present in 24% of subjects, while no case of osteoporosis was documented. Duration and dosage of valproate monotherapy did not correlate with BMD. No association was documented between duration or dosage of valproate monotherapy and biochemical parameters. Conclusions Duration of valproate monotherapy does not correlate with decreased BMD in adult patients with epilepsy. No case of osteoporosis was identified in patients treated with valproate for a mean period of more than ten years. These findings indicate that bone metabolism may not be affected by valproate monotherapy.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20056251</pmid><doi>10.1016/j.jns.2009.12.015</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-510X |
| ispartof | Journal of the neurological sciences, 2010-03, Vol.290 (1), p.131-134 |
| issn | 0022-510X 1878-5883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_883046606 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Absorptiometry, Photon Adult Age Anticonvulsants - administration & dosage Anticonvulsants - adverse effects Biological and medical sciences Biomarkers - analysis Biomarkers - blood Bone and Bones - drug effects Bone and Bones - metabolism Bone and Bones - physiopathology Bone Density - drug effects Bone Density - physiology Bone Diseases, Metabolic - chemically induced Bone Diseases, Metabolic - pathology Bone Diseases, Metabolic - physiopathology Bone mineral density Bone turnover Calcium (blood) Chronic Disease Cross-Sectional Studies Drug Administration Schedule Dual energy X-ray absorptiometry Epilepsy Female Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Magnesium Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Osteopenia Osteoporosis Osteoporosis - chemically induced Osteoporosis - pathology Osteoporosis - physiopathology Phosphorus Time Time Factors Valproate Valproic acid Valproic Acid - administration & dosage Valproic Acid - adverse effects Young Adult |
| title | Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T11%3A02%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20long-term%20valproate%20monotherapy%20on%20bone%20mineral%20density%20in%20adults%20with%20epilepsy&rft.jtitle=Journal%20of%20the%20neurological%20sciences&rft.au=Triantafyllou,%20Nikos&rft.date=2010-03-15&rft.volume=290&rft.issue=1&rft.spage=131&rft.epage=134&rft.pages=131-134&rft.issn=0022-510X&rft.eissn=1878-5883&rft.coden=JNSCAG&rft_id=info:doi/10.1016/j.jns.2009.12.015&rft_dat=%3Cproquest_cross%3E733514942%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733514942&rft_id=info:pmid/20056251&rft_els_id=1_s2_0_S0022510X09010065&rfr_iscdi=true |